Monster Energy's Kayla Harrison Defeats Amanda Nunes to Retain Women's Bantamweight Championship at UFC 334

CG PARTNERS LIMITED PARTNERSHIP ENTERS INTO VOTING AND SUPPORT AGREEMENT IN CONNECTION WITH PROPOSED GO-PRIVATE TRANSACTION OF CANACCORD...

Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for...

CANACCORD GENUITY GROUP INC. REPORTS SECOND QUARTER FISCAL 2027 RESULTS

CANACCORD GENUITY GROUP INC. ENTERS INTO AGREEMENT TO BE TAKEN PRIVATE BY CHAIRMAN AND CEO DAN DAVIAU

CANACCORD GENUITY GROUP INC. ANNOUNCES SALE OF ITS WEALTH MANAGEMENT BUSINESS IN THE UK & CROWN DEPENDENCIES TO CENTERBRIDGE PARTNERS, L...

Mesoblast Showcased at ASX Premier Investor Day Event

Parliamentary Secretary Ehsassi highlights Government of Canada's investments from Budget 2026: Masters of our destiny

DeGen Medical Moves to Dismiss Carlsmed Patent Suit, Vows to Fight Remaining Claims

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Millrose Properties, Inc. Investors to Secure Counsel Before Important Deadline in...

12/OC to Headline Toys for Tots Charity Event at Grace Event Center

Plumbing Detectives LLC Publishes a First-Hour Plumbing Checklist for Seasonal Residents Returning to Venice, Florida Homes

Berry Street Welcomes MyScribe Founder Dr. Wasif Bokhari to Its AI Team and Acquires MyScribe

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages D-Wave Quantum Inc. Investors to Secure Counsel Before Important Deadline in...

RECALIBRATE NEURAL RIGS Releases New Research exposing "The 50-ms Problem" in Baseball Hitting

Global Sarcoma Therapy Now Available in Thailand

NerveHoney Introduces Nerve Honey Capsules, a Multi-Ingredient Dietary Supplement for Nerve Health Support

AlkaFit Introduces Alka Fit Capsules- A Six-Ingredient Dietary Supplement for Weight Management

HoneySlim Introduces Honey Slim Capsules, a Multi-Ingredient Dietary Supplement for Metabolic and Appetite Support

IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in...